Retrieved November 20, 2024, from
Aoun L, Almardini S, Saliba F, Haddadin F, Mourad O, Jdaidani J, Morcos Z, Al Saidi I, Bou Sanayeh E, Saliba S, Almardini M, Zaidan J
Archived (PDF) from the original on 5 May 2020
Efficacy Type 2 Diabetes SURPASS-2 Trial A direct comparison between tirzepatide and semaglutide in the SURPASS-2 trial demonstrated: HbA1c reduction : Tirzepatide (15 mg): up to 2.3% Semaglutide (1 mg): 1.9% Average weight loss : Tirzepatide: 5.5 kg Semaglutide: 3.8 kg Meta-Analysis Findings A meta-analysis of multiple trials confirmed tirzepatides superiority: 5 mg dose : 1.5 higher odds of achieving 5% weight loss than semaglutide 10 mg dose : 3.0 higher odds 15 mg dose : 4.2 higher odds However, higher tirzepatide doses also led to slightly higher discontinuation rates due to gastrointestinal side effects
for weight management
Due to irritation to the throat, it is advisable not to take alpha-lipoic acid as a liquid, such as alpha-lipoic acid mixed in water [1]